Tridek One, Paris, June 4, 2019 – Tridek One, a biotech company specialized in the development of products for the treatment of immune disorders, is pleased to announce a first round of funding of 3 million euros with leading investors Advent France Biotechnology and Advent Life Sciences.
Tridek-One obtained 500k€ from BPI “Aide au développement et à l’innovation” program
Tridek-One signed an exclusive license and a collaboration agreement to develop CD31 agonist
